Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.35 |
| ▸ | RAF1 | P04049 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 5/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 3/20 | 0.32 |
| ▸ | PRKDC | P78527 | 2/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391901 | 0.88 | SCN9A (0.38) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL387910 | 0.86 | SCN9A (0.38) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL392100 | 0.85 | BRAF (0.40) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL388897 | 0.85 | SCN9A (0.38) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL393597 | 0.85 | SCN9A (0.38) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL391710 | 0.84 | SCN9A (0.38) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL1339260 | 0.84 | SCN9A (0.37) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL392624 | 0.83 | SCN9A (0.41) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL1339059 | 0.81 | ADORA2A (0.35) | BRAFSCN9AIRAK1IRAK4CCND1 | |
| SCHEMBL391680 | 0.81 | SCN9A (0.38) | BRAFRAF1SCN9AIRAK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101628-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2125793-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, BUB1B, BUB1 | BRAF 1075/4885RAF1 1127/4885SCN9A 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.